Hair cortisol may act as molecular biomarker for retinitis pigmentosa patients

Article

Patients with retinitis pigmentosa experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.

Hair cortisol may act as molecular biomarker for retinitis pigmentosa patients

Dr Milagros Mateos and colleagues from the Department of Ophthalmology of Clinical University Hospital of Valladolid and the Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain, reported that the concentration of cortisol in hair may be an effective biomarker associated with chronic stress in patients with retinitis pigmentosa.

The authors explained that patients with RP experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair. The stress is associated with the progressive and unpredictable and variable vision loss associated with the disease.

Study of hair samples

Dr Mateos and associates conducted a study in which they included 87 patients who were recruited from the Association of RP Patients from Casilla y Leon, Spain, between January 2019 and June 2021. The study also included 148 healthy controls.

All participants underwent an ophthalmologic examination that included clinical, structural, and functional tests, the results of which would be used divide patients by disease severity. An enzyme-linked immunosorbent assay was used to analyze the hair strands, and a questionnaire was administered to measure stress and anxiety levels.

Analysis results of RP by disease severity

The investigators reported that two-thirds of patients with RP had severe disease and the remaining third a mild-moderate stage of disease.

The questionnaire results indicated that 58 (58.9%) patients reported severe stress and anxiety and 18 (23.1%) highly elevated levels.

The patients with retinitis pigmentosa had higher level of cortisol in the hair samples (2.62 ± 0.14 Log10 pg/mg) compared with the controls (1.99 ± 0.23 Log10 pg/mg; P < 0.001). The patients with severe disease had significantly higher levels of cortisol in their hair than patients with mild-moderate RP, 2.71 ± 0.12 Log10 pg/mg and 2.43 ± 1.17 Log10 pg/mg (P < 0.011), respectively.

In addition, the severely anxious patients obtained a log-hair cortisol concentration that was higher than the patients experiencing less stress, 2.70 ± 0.24 Log10 pg/mg vs. 2.49 ± 0.19 Log10 pg/mg, although, the research team reported, the RP severity grade and perceived anxiety levels in the questionaries were not associated.

Dr Mateos and colleagues concluded, “The hair cortisol concentration seems to be an effective biomarker associated with chronic stress in patients with RP. This study shows that the hair cortisol concentrations in patients with RP are elevated compared to population-based controls, and an association between the concentration level and RP severity was identified. Future research is needed to characterize the effect of this untreated negative psychological states on progression of the disease if any.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.